Taxane analogues: Distinguishing royal robes from the "Emperor's New Clothes"

Clinical Cancer Research

Volumn 8, Issue 9, 2002, Pages 2759-2763

  Rowinsky, Eric K ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; BMS 184476; DEXTRAN; DOCETAXEL; DOCOSAHEXAENOIC ACID; GLUTAMIC ACID; GLYCOPROTEIN P; INTERCALATING AGENT; LIPOSOME; OMEGA 3 FATTY ACID; PACLITAXEL; POLYAMINOACID; POLYMER; RICINOMACROGOL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER CHEMOTHERAPY; CELL MEMBRANE; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; EDITORIAL; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA; LUNG NON SMALL CELL CANCER; MICROTUBULE ASSEMBLY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR XENOGRAFT;

ALKALOIDS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS, PHASE I; DRUG EVALUATION; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PACLITAXEL; TAXOIDS;

EID: 0036718431     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (29)

1. Intercalators as anticancer drugs
2. Recurrent epithelial ovarian carcinoma: A randomized Phase III study of pegylated liposomal doxorubicin versus topotecan
3. Multicenter Phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
4. Current status of chemotherapy for ovarian cancer
5. Drug therapy: Paclitaxel (Taxol)
6. Progress in the development of alternative pharmaceutical formulations of taxanes
7. New taxanes and epotholone derivatives in clinical trials
8. Taxol: Mechanisms of action and resistance
9. Phase I pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies
10. Preclinical antitumor activity of two novel taxanes
11. Preclinical antitumor activity of a new paclitaxel analog BMS-184476
12. Synthesis and antitumor activity of novel C-7 paclitaxel ethers: Discovery of BMS-184476
13. The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells
14. European-Canadian randomized trial of Taxol in relapsed ovarian cancer: High versus low dose and long versus short infusion
15. Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations
16. 3H]-paclitaxel in rats: A quantitative autoradiographic study
17. 14C-RP 56976) in mice and dogs
18. Taxol metabolism and disposition in cancer patients
19. The taxanes: Dosing and scheduling considerations
20. Weekly paclitaxel in the management of ovarian cancer
21. Weekly docetaxel in breast cancer: Applying clinical data to patient therapy
22. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
23. A randomized trial of paclitaxel at 2 dose levels and Filgastrim (G; G-CSF) at 2 dose levels in platinum pretreated epithelial ovarian cancer (OVCA): A Gynecologic Oncology Group, SWOG, NCTTG and ECOG study
24. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
25. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: Results from CALGB 9342
26. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with paclitaxel-cisplatin versus etoposide-cisplatin: Results from an Eastern Cooperative Oncology Group trial
27. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin
28. A Phase III comparison of high-dose Taxol + cisplatin + G-CSF versus low-dose Taxol + cisplatin in advanced head and neck cancer: An ECOG study (E1393)
29. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel